true

Support

Singapore (Greater Asia Head Office)

+65 6664 2700

bd_sea@bd.com

Submit a form online

Thank you for contacting our sales team!

A sales representive will get in touch with you shortly.

Address

2 International Business Park Road, #08-08 The Strategy, Singapore 609930

Bloodstream Infection

What if you had an integrated bloodstream infection (BSI) diagnostics solution that empowered you with actionable results to inform and impact patient care?

The integrated, end-to-end BD Bloodstream Infection Solution

The integrated, end-to-end BD Bloodstream Infection Solution brings together proven, quality solutions across the entire bloodstream infection diagnostic continuum — from world-class blood culture collection to accurate, timely and actionable results — helping you to optimize time, resources and decision-making to drive improved patient outcomes.

Diagnosis of bloodstream infections is challenging as time is of the essence and stakes are high

1.7 million sepsis cases are reported each year in the US, contributing to approximately a third of all hospital deaths.^1-350% of septic patients in the ICU have bacteremia, which increases the risk of septic shock and death as compared to non-bacteremic sepsis.^4,5 Blood cultures are an essential tool in the diagnostic workup of patients with signs of sepsis.

Although sepsis carries a high burden, it's estimated that about 80% of septic shock patients survive when appropriate antibiotic therapy is started within the first hour following onset of hypotension.⁶

What if you could quickly and accurately obtain actionable results to support faster antibiotic decision making and contribute to improving patient outcomes ?

Consistently collect high-quality blood culture specimens

BD offers world-class blood culture collection products that enable phlebotomy and nursing staff to collect the high-quality specimens that labs and clinicians need to make a timely diagnosis and appropriate treatment decisions. 

First, the BD Vacutainer^® UltraTouch™ Push Button Blood Collection Set is designed to simplify the collection process, reduce perceived pain and accelerate fill times, ultimately improving the chance of collecting a high-quality specimen and enhancing the patient’s experience.^7-11

Then, by adding the Magnolia Steripath^® Initial Specimen Diversion Device^®, you can achieve near-zero blood culture contamination rates.^12-16

Improve time to microbial detection and organism recovery

The BD Bloodstream Infection Solution includes a complete line of blood culture media formulations and scalable, modular instrumentation that can be deployed near the point of collection to support faster time to incubation and reduced time to appropriate treatment.^17-20

Expedite antibiotic therapy decisions with fast actionable phenotypic susceptibility results

Acutely ill patients with septic shock cannot wait for optimal antimicrobial treatment and clinicians need timely actionable results to inform treatment decisions and improve patient outcomes.^6,23

With the speed and simplicity of the Accelerate Pheno^® system, microorganism identification and actionable phenotypic susceptibility results based on minimum inhibitory concentrations (MIC) are available in approximately 7 hours directly from positive blood culture samples, supporting faster initiation of optimal therapy and expanding the value of antimicrobial stewardship.^24-30

Ensure accurate pathogen identification and extensive antibiotic coverage

With an extensive panel format, true doubling dilutions, and extended breakpoints, the BD Phoenix™ Automated Identification and Antimicrobial Susceptibility Testing System marries performance with ease of use to provide timely and accurate detection of known and emerging antimicrobial resistance that supports your antimicrobial stewardship efforts.^34-39

Access meaningful and actionable insights anytime, anywhere

Monitoring, analyzing and communicating microbiology data in a timely manner can directly impact patient care.^40,41 However, obtaining, organizing and communicating this information is labor intensive 

The BD informatics solutions empower you with actionable information and analytics that can be used to drive continuous improvement of blood collection practices and laboratory workflows, as well as the ability to communicate results in a timely manner to key stakeholders.^18,41

Support faster initiation of optimal therapy and antimicrobial stewardship efforts

Delayed or inappropriate initial antimicrobial therapy for bloodstream infection results in prolonged hospital stays and increased mortality rates, while contributing to the silent pandemic of antimicrobial resistance.^42-44 

Implementing the BD Bloodstream Infection Solution, which includes the Accelerate Pheno^® system, can help reduce time to antimicrobial susceptibility results by 40 hours, reduce time to optimal therapy by over a day and reduce length of stay by up to 1.8 days, compared to conventional methods.^24-28,45,46

Strive for clinical and operational excellence across the bloodstream infection diagnostic continuum

Our clinical solution

It can be difficult to identify the root cause of issues along the diagnostic pathway that may influence the quality of results. Without knowing where to make improvements, you won’t know where to invest time, resources or training. Furthermore, the bloodstream infection diagnostic pathway is complex and involves a great number of stakeholders.  

The BD Clinical Specialists can help you quickly and easily gain insights across your current bloodstream infection diagnostic pathway by objectively understanding and quantifying challenges, risks and inefficiencies, along with giving you tailored BD solutions and recommendations to address your specific needs.

With the expertise of BD Clinical Specialists

combined with the insights generated from BD Informatics, you’ll be empowered to...^41,47

Reduce variability and inefficiencies

that create waste and risk
Establish greater accountability

by sharing insights and metrics
Maintain adherence to best practices

and potentially improve patient experience and outcomes

Unparalleled bloodstream infection solutions for clinicians, laboratories and operational teams each step along the bloodstream infection pathway

As your trusted partner, we are committed to helping you make sustainable clinical and economic impact through a holistic approach to bloodstream infection management. We do so by empowering your teams with tools and technologies that support quality, accuracy and efficiency improvements across all stages of the bloodstream infection diagnostic pathway.

ED nurses, phlebotomists

The BD Bloodstream Infection Solution, which includes the BD Vacutainer^® UltraTouch™ Push Button Blood Collection Set and the Magnolia Steripath^® Initial Specimen Diversion Device^®, empowers you to quickly and consistently fill blood culture bottles with near-zero blood culture contamination rates, giving you a better chance to collect the high-quality specimens that labs and clinicians need to make a timely diagnosis and appropriate treatment decisions^8-16,41,48 — with the additional benefit of improved protection against accidental needlestick injuries.^49,50

Laboratories

The integrated BD Bloodstream Infection Solution addresses all your BSI diagnostic needs — from specimen collection and blood culture to identification and susceptibility testing — with speed, accuracy and efficiency, and empowers you with actionable insights that can be used to drive continuous improvement of blood collection practices, minimize time to results and optimize resources.^{10,18,24,29,31,32,41,47,48}

Sepsis coordinators

The integrated BD Bloodstream Infection Solution allows you to strengthen the connection between your laboratory and nursing stakeholders, establishing greater long-term accountability both inside and outside of the lab and ensuring that your teams can consistently and effectively adhere to blood culture collection and testing best practices.^12,41,47

Infectious disease specialists

The combination of BD informatics and BD instruments as part of the BD Bloodstream Infection Solution helps you actively find ways to achieve and maintain the highest quality all along the bloodstream infection pathway. With our complementary identification and antimicrobial susceptibility testing instruments, you will be empowered to quickly and accurately translate actionable laboratory results into appropriate patient treatment and react to emerging resistance or healthcare-associated infection events.^{29,38,39,41,47}

Hospital leaders

By connecting all the steps from specimen collection to results reporting, the integrated BD Bloodstream Infection Solution helps you drive antimicrobial stewardship, reduce hospital length of stay, make substantial savings and enhance your Centers for Medicare & Medicaid Services (CMS) key quality outcome metrics and reimbursement.^{15,18,26-29,38,39,51-54}

Heritage

Through our purpose rooted in Advancing the World of Health™ for over 125 years, combined with over 40 years of experience in bloodstream infection diagnostics, we continue to be a pioneer in bloodstream infection diagnosis.
Innovation

We understand the challenges you face every day. As your partner, we are committed to continuously invest in innovation and help you elevate the standard of care for bloodstream infection diagnostics.
Partnership

We provide you with an unparalleled end-to-end bloodstream infection diagnostics solution thanks to our robust portfolio and our strategic partnerships with Magnolia Medical Technologies, Accelerate Diagnostics and Bruker.

CDC. What is Sepsis? Updated August 24, 2023. https://www.cdc.gov/sepsis/what-is-sepsis.html. Accessed August 31, 2023
Rhee C et al. JAMA. 2017;318(13):1241–9
Rhee C et al. JAMA Netw Open. 2019;2(2):e187571
Mellhammar L et al. Sci Rep. 2021;11(1):6972
Komori A et al. Sci Rep. 2020;10(1):2983
Kumar A et al. Crit Care Med. 2006;34(6):1589–96
Mouser A et al. J Appl Lab Med. 2017;2(2):201–10
Merrill VD et al. J Appl Lab Med. 2022;7(2):532–40
Padoan A et al. Clin Chim Acta. 2020;500:213–9
BD Study Summary VS9249-2. 2021
BD Study Summary VS9248-2. 2021
Bell M et al. J Emerg Nurs. 2018;44(6):570–5
Arenas M et al. J Emerg Nurs. 2021;47(2):256–64
Zimmerman FS et al. Am J Infect Control. 2019;47(7):822–6
Nielsen LE et al. J Hosp Infect. 2021;120:127–33
Povroznik MD. Am J Med Qual. 2022;37(5):405–12
Zadroga R et al. Clin Infect Dis. 2013;56(6):790–7
Bruins MJ et al. Eur J Clin Microbiol Infect Dis. 2017;36(4):619–23
Almuhayawi M et al. PLoS ONE. 2015;10(11):e0142398
Rocchetti A et al. J Microbiol Methods. 2016;130:129–32
Rohner P et al. J Clin Microbiol. 1997;35(10):2634–8
Li G et al. Front Cell Infect Microbiol. 2019;9:285
O'Neill J et al. "Tackling drug-resistant infections globally: Final report and recommendations" in the Review on Antimicrobial Resistance. 2016. https://amr-review.org/Publications.html. Accessed 22 Jun 2023
Charnot-Katsikas A et al. J Clin Microbiol. 2018;56(1):e01166–17
Banerjee R et al. Clin Infect Dis. 2021;73(1):e39–e46
Dare RK et al. Clin Infect Dis. 2021;73(11):e4616–26
Walsh TL et al. Infection. 2021;49(3):511–9
Sheth S et al. Antimicrob Agents Chemother. 2020;64(9):e00578–20
Bhalodi AA et al. Clin Infect Dis. 2022;75(2):269–77
Roth F et al. Antibiotics. 2022;11(2):122–6
Saffert RT et al. J Clin Microbiol. 2011;49(3):887–92
Knabl L et al. Lett Appl Microbiol. 2021;73(1):2–8
Watanabe N et al. J Infect Chemother. 2022;28(4):563–8
BD Phoenix™ M50 Automated Microbiology System User's Manual (500008930)
Carey RB et al. Failure of Automated Systems to Detect Vancomycin-Resistant Staphylococcus aureus. Abstract presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), Washington, DC, 2004
Tenover FC et al. Emerg Infect Dis. 2006;12(8):1209–13
Kulah C et al. BMC Infect Dis. 2009;9:30
Mittman SA et al. J Clin Microbiol. 2009;47(11):3557–61
Woodford N et al. J Clin Microbiol. 2010;48(8):2999–3002
CDC. Preventing Adult Blood Culture Contamination: A Quality Tool for Clinical Laboratory Professionals. Available at: https://www.cdc.gov/labquality/docs/BCC-Prevention_A-Quality-Tool_CDC.pdf. Accessed October 2023
Khare R et al. Clin Infect Dis. 2020;70(2):262–8
Battle SE et al. J Antimicrob Chemother. 2017;72(1):299–304
Burnham J et al. Open Forum Infect Dis. 2017 Oct 4;4(Suppl 1):S623–4
Bauer KA et al. Open Forum Infect Dis. 2022;9(11):ofac537
Marschal M et al. J Clin Microbiol. 2017;55(7):2116–26
Lutgring JD et al. J Clin Microbiol. 2018;56(4):e01672-17
Lippi G et al. Clin Chem Lab Med. 2011;49(7):1113–26
Garcia RA et al. Am J Infect Control. 2015;43(11):1222–37
Hotaling M. Jt Comm J Qual Patient Saf. 2009;35(2):100–5
Dicristina DL. Successfully reducing wingset-related needlestick injuries: A combination of institutional culture, staff commitment and semi-passive safety device. AOHP. Spring 2014. https://www.bd.com/resource.aspx?IDX=31023
Geisler BP et al. J Hosp Infect. 2019;102(4):438–44
Skoglund E et. J Clin Microbiol. 2019;57(1):e01015-18
Self W et al. Infect Control Hosp Epidemiol. 2014;35(8):1021–8
Tompkins LS et al. Infect Control Hosp Epidemiol. 2023;44(9):1386–90